The impact of timing and prioritization on the cost‐effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States

Phil McEwan, Thomas Ward, Yong Yuan, Ray Kim, Gilbert L'Italien – 6 February 2013 – Recent United States guidelines recommend one‐time birth cohort testing for hepatitis C infection in persons born between 1945 and 1965; this represents a major public health policy undertaking. The purpose of this study was to assess the role of treatment timing and prioritization on predicted cost‐effectiveness.

Wnt5a signaling mediates biliary differentiation of fetal hepatic stem/progenitor cells in mice

Kei Kiyohashi, Sei Kakinuma, Akihide Kamiya, Naoya Sakamoto, Sayuri Nitta, Hideto Yamanaka, Kouhei Yoshino, Junko Fujiki, Miyako Murakawa, Akiko Kusano‐Kitazume, Hiromichi Shimizu, Ryuichi Okamoto, Seishin Azuma, Mina Nakagawa, Yasuhiro Asahina, Naoki Tanimizu, Akira Kikuchi, Hiromitsu Nakauchi, Mamoru Watanabe – 5 February 2013 – The molecular mechanisms regulating differentiation of fetal hepatic stem/progenitor cells, called hepatoblasts, which play pivotal roles in liver development, remain obscure.

Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma

Jiaxin Xie, Yuwei Zhang, Qi Zhang, Yifang Han, Jianhua Yin, Rui Pu, Qiuxia Shen, Wei Lu, Yan Du, Jun Zhao, Xue Han, Hongwei Zhang, Guangwen Cao – 5 February 2013 – Hepatitis B virus (HBV) mutations and signal transducer and activator of transcription 3 (STAT3) activation are closely associated with hepatocellular carcinoma (HCC). However, single nucleotide polymorphisms (SNPs) of STAT3 have not been implicated in HCC susceptibility. This study was designed to evaluate the effect of STAT3 SNPs and their interactions with HBV mutations on HCC risk.

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

Stuart C. Gordon, Zahary Krastev, Andrzej Horban, Jörg Petersen, Jan Sperl, Phillip Dinh, Eduardo B. Martins, Leland J. Yee, John F. Flaherty, Kathryn M. Kitrinos, Vinod K. Rustgi, Patrick Marcellin – 30 January 2013 – We evaluated the antiviral response of patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as having hepatitis B virus (HBV) DNA ≥9 log10 copies/mL, after 240 weeks of tenofovir disoproxil fumarate (TDF) treatment.

Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: Effect of patient and nonpatient factors

Jessica A. Davila, Jennifer R. Kramer, Zhigang Duan, Peter A. Richardson, Gia L. Tyson, Yvonne H. Sada, Fasiha Kanwal, Hashem B. El‐Serag – 28 January 2013 – The delivery of treatment for hepatocellular carcinoma (HCC) could be influenced by the place of HCC diagnosis (hospitalization versus outpatient), subspecialty referral following diagnosis, as well as physician and facility factors. We conducted a study to examine the effect of patient and nonpatient factors on the place of HCC diagnosis, referral, and treatment in Veterans Administration (VA) hospitals in the United States.

Predictors of poor outcome in patients w ith autoimmune hepatitis: A population‐based study

Jing Hieng Ngu, Richard Blair Gearry, Chris Miles Frampton, Catherine A.M. Stedman – 28 January 2013 – Autoimmune hepatitis (AIH) can lead to cirrhosis, hepatic failure, and death. We aimed to identify predictors of advanced liver fibrosis at presentation, predictors of incomplete response to initial immunosuppression, and predictors of poor liver‐related outcomes in the population‐based AIH cohort from Canterbury, New Zealand. Cases diagnosed after 1980 that fulfilled standard diagnostic criteria were included.

Subscribe to